Compare XPON & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPON | PULM |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 6.1M |
| IPO Year | 2022 | 2013 |
| Metric | XPON | PULM |
|---|---|---|
| Price | $3.30 | $1.65 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 80.2K | 24.6K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.63 | 46.18 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,651,870.00 | $7,910,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 71.59 | ★ 5069.93 |
| 52 Week Low | $0.26 | $1.16 |
| 52 Week High | $5.50 | $5.80 |
| Indicator | XPON | PULM |
|---|---|---|
| Relative Strength Index (RSI) | 84.03 | 55.11 |
| Support Level | $0.58 | $1.59 |
| Resistance Level | N/A | $1.88 |
| Average True Range (ATR) | 0.17 | 0.11 |
| MACD | 0.38 | -0.01 |
| Stochastic Oscillator | 85.25 | 44.27 |
Expion360 Inc focuses on the design, assembly, manufacturing, and sale of lithium iron phosphate (LiFePO4) batteries and related accessories for RV, marine, and industrial applications. Its high-performance battery solutions are designed for high energy density and a compact footprint, supported by engineering and intellectual property to enhance safety, quality, and performance. The company also engages in product design, development, and collaboration to strengthen customer relationships. It serves dealers, wholesalers, private-label customers, and OEMs, who distribute its products to end consumers. Its segment is Energy Storage (ES), providing lithium-based energy solutions backed by durable materials, optimized internal structures, and responsive customer service.
Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).